| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/01/2006 | EP1408768B1 SUGAR-FREE HARD COATINGS PREPARED FROM LIQUID MALTITOL COMPRISING DP sb 4+ /sb FRACTION |
| 03/01/2006 | EP1379203B1 Condom with an erectogenic composition |
| 03/01/2006 | EP1352654B1 Famotidine injections |
| 03/01/2006 | EP1351972B1 Lipids comprising an aminoxy group |
| 03/01/2006 | EP1325739B1 Liposomes encapsulating anticancer drugs and the use thereof in the treatment of malignant tumors |
| 03/01/2006 | EP1240230B1 Swelling and deswelling polymer blends |
| 03/01/2006 | EP1196143B1 Use of an electric field for sensitising red blood cells to ultrasound |
| 03/01/2006 | EP1178778B1 Granules containing a plant substance and method for producing the same |
| 03/01/2006 | EP1133285B1 A process for producing particles with a converted amorphous and/or meta-stable crystalline region into crystalline state |
| 03/01/2006 | EP1127355B1 Products and methods for brachytherapy |
| 03/01/2006 | EP1123082B1 Preparations for topical application of substances having antiandrogenic effect |
| 03/01/2006 | EP1105409B1 Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| 03/01/2006 | EP1067927B1 Antioxidant stabilizer system for pharmaceutical formulations |
| 03/01/2006 | EP1003556B1 Cationic reagents for transfection |
| 03/01/2006 | EP0973552B1 Improvements in or relating to diagnostic/therapeutic agents |
| 03/01/2006 | EP0959873B1 Gel composition and methods |
| 03/01/2006 | EP0941315B1 Fusion proteins containing stress proteins for inducing immune responses |
| 03/01/2006 | CN1741819A Sustained release composition for oral administration of drugs |
| 03/01/2006 | CN1741814A Modified naturetic compounds, conjugates, and uses thereof |
| 03/01/2006 | CN1741804A Freeze-dried preparation of stabilized anthracycline compound |
| 03/01/2006 | CN1741794A A topical nanoparticulate spironolactone formulation |
| 03/01/2006 | CN1741787A Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same |
| 03/01/2006 | CN1739804A Saccharide composition with protection on microecologic prepn |
| 03/01/2006 | CN1739537A Cyclodextrin clathrate of breviscapine and its prepn |
| 03/01/2006 | CN1739530A Aspirin-Al-lysine for injection |
| 03/01/2006 | CN1739525A Nanometer partical administration system of prostaglandin E1 coated with polyglycol derived phospholipid |
| 03/01/2006 | CN1739500A (-)-epigallocatechin gallate-magnesium complex solid dispersion and its prepn and application |
| 03/01/2006 | CN1739499A (-)-epigallocatechin gallate solid dispersion and its prepn and application |
| 03/01/2006 | CN1739498A (-)-epigallocatechin gallate-calcium complex solid dispersion and its prepn and application |
| 03/01/2006 | CN1739491A Nanometer fiber slow-releasing system and its prepn process and application |
| 03/01/2006 | CN1739487A Medicine gel spray and its prepn |
| 03/01/2006 | CN1243826C Biofilm carrier with improved specific surfacial area, bio-affinity and flowability |
| 03/01/2006 | CN1243779C Hydrophilic polymer derivative having Y shaped branch, its preparation method, combined object with medicine molecule and medical composition containing combined object |
| 03/01/2006 | CN1243570C Anti-tumour magnetic targeted slow release carrier iron-carbon composite material and its preparation method |
| 03/01/2006 | CN1243569C Use of active P40 conjugates for nasal delivery |
| 03/01/2006 | CN1243559C Herbal composition and medicament against diabetes mellitus type II manufactured thereof |
| 03/01/2006 | CN1243551C Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response |
| 03/01/2006 | CN1243549C Ursolic acid cyano acrylic ester nano particle freeze dried powder for ampoule agent and its preparation method |
| 03/01/2006 | CN1243548C Eye drops |
| 03/01/2006 | CN1243547C New formulation |
| 03/01/2006 | CN1243546C Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations |
| 03/01/2006 | CN1243544C Taxusol composition and its preparing process |
| 03/01/2006 | CN1243543C Bioimplant formulation |
| 03/01/2006 | CN1243539C Process for producing stable enteric sugar-coated tablet |
| 03/01/2006 | CN1243538C Ursolic acid bean phospholipid nano particle freeze drying powder for ampoule agent and its preparation method |
| 03/01/2006 | CN1243537C Use of composition containing at least one oxidative sensitive hydrophilic active ingredient through at least one maleic anhydride copolymer stabilization at cosmetic and /or skin |
| 02/28/2006 | US7005557 Film-forming compositions for protecting skin from body fluids and articles made therefrom |
| 02/28/2006 | US7005504 Antiinflammatory agents |
| 02/28/2006 | US7005454 Dispersion of water soluble drug in water insoluble polymer matrix |
| 02/28/2006 | US7005448 Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma |
| 02/28/2006 | US7005421 Doxorubicin hydrochloride acidic solution which has not been reconstituted from lyophilizate |
| 02/28/2006 | US7005420 Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
| 02/28/2006 | US7005408 Anhydrous warming, non- toxic and nonirritating lubricating compositions containing polyhydric alcohols and an insulating agent. The invention also relates to methods of using such compositions for lubrication, administration of active |
| 02/28/2006 | US7005300 based on carbohydrates; for transfer of DNA and RNA polynucleotides into eukaryotic cells in vivo or in vitro; drug delivery; gene therapy |
| 02/28/2006 | US7005145 Antibacterial and fungicidal polymer dispersions and polymer solutions |
| 02/28/2006 | US7005141 Modified amino acids and derivatives can form non-covalent mixtures with active biological agents and in an alternate embodiment can releasably carry active agents. Modified amino acids can also form drug containing microspheres. |
| 02/28/2006 | US7005140 composition that includes a charged lipid for interaction with a charged therapeutic agent, yet which bears minimal external surface charge after formation. |
| 02/28/2006 | US7005133 Composition and process for treating pollution |
| 02/28/2006 | US7005132 Drugs specifically bound to synthetic receptors in such a manner that active drug becomes available only in the presence of a targeted pathophysiologic receptor. |
| 02/28/2006 | US7005124 High drug efficiency, high drug carrying capacity, good water solubility, good stability on storage, reduced toxicity, and improved anti-tumor activity in vivo |
| 02/28/2006 | US7005123 Functional poly-α-amino-acid derivatives useful for the modification of biologically active materials and their application |
| 02/28/2006 | US7005122 Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route |
| 02/28/2006 | US7005121 Arerosol; heating drug, vaporization, cooling |
| 02/28/2006 | CA2123946C Cyclodextrin inclusion product of paclitaxel, process for producing the same, and its use |
| 02/23/2006 | WO2006020743A2 Heat shock protein as a targeting agent for endothelium-specific in vivo transduction |
| 02/23/2006 | WO2006020722A2 Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting |
| 02/23/2006 | WO2006020719A2 Aminoacid conjugates of beta - lapachone for tumor targeting |
| 02/23/2006 | WO2006020403A2 3-halo-2-oxopropionate salts and esters as novel anticancer agents |
| 02/23/2006 | WO2006020208A2 Therapeutic composition whit a botulinum neurotoxin |
| 02/23/2006 | WO2006019950A2 Conjugates of a gm-csf moiety and a polymer |
| 02/23/2006 | WO2006019140A1 Jelly composition |
| 02/23/2006 | WO2006018698A2 Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract |
| 02/23/2006 | WO2006018392A1 Aerosol formulation for inhalation, containing an anticholinergenic agent |
| 02/23/2006 | WO2006018135A1 Use of amphiphilic copolymers as solubilising agents |
| 02/23/2006 | WO2006002419A3 Cross-linked cellulose ii |
| 02/23/2006 | WO2005115474B1 Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| 02/23/2006 | WO2005107814A3 Process for the preparation of doxorubicin conjugates with lactosaminated human albumin and the obtained conjugates |
| 02/23/2006 | WO2005093422A3 Carbohydrate-encapsulated quantum dots for biological imaging |
| 02/23/2006 | WO2005077424A3 Conjugate for destroying cancer cells |
| 02/23/2006 | WO2005058364A3 Preservative system |
| 02/23/2006 | WO2005045040A3 RNA INTERFERANCE MEDIATED INHIBITION OF CHOLINERGIC MUSCARINIC RECEPTOR (CHRM3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID /siNA) |
| 02/23/2006 | WO2005040342A3 Cleavage of rna by restriction endonucleases |
| 02/23/2006 | WO2005016257A3 Process of making flowable hemostatic compositions and devices containing such compositions |
| 02/23/2006 | WO2004078137A3 Antitumor agents comprising a targeting portion and an immune response triggering portion |
| 02/23/2006 | US20060041105 Peptides whose uptake by cells is controllable |
| 02/23/2006 | US20060041009 Pharmaceutical compound containing silymarin and carbopol, production method thereof and use of same as a regenerator of tissue and pancreatic cells with endogenous secretion damaged by diabetes mellitus |
| 02/23/2006 | US20060040912 Compounds for pdt |
| 02/23/2006 | US20060040310 Epitope testing using soluble HLA |
| 02/23/2006 | US20060039997 Multiparticulate formulations of lithium salts for oral administration suitable for once-a-day administration |
| 02/23/2006 | US20060039989 Pharmaceutical compositions of cell lysate and processes for the production and use thereof |
| 02/23/2006 | US20060039988 Azithromycin dosage forms with reduced side effects |
| 02/23/2006 | US20060039981 Taste masked dosage forms and processes for their preparation |
| 02/23/2006 | US20060039978 Self-forming phospholipidic gels |
| 02/23/2006 | US20060039970 Tamper-resistant oral opioid agonist formulations |
| 02/23/2006 | US20060039969 Gastrointestinal side effect reduction with lower mean Maximum concentrations (Cmax) than with an immediate release formulation, but equivalent bioavailability of clarithromycin and a water soluble alginate salt, a complex salt of alginic acid and an organic carboxylic acid |
| 02/23/2006 | US20060039965 Drug delivery system for hydrophobic drugs |
| 02/23/2006 | US20060039964 Micelle assemblies |
| 02/23/2006 | US20060039962 Amphiphilic compounds and vesicles liposomes for organ-specified drug targeting |
| 02/23/2006 | US20060039960 Plaster containing fentanyl |
| 02/23/2006 | US20060039959 Film-Shaped Mucoadhesive Administration Forms For Administering Cannabis Agents |